Practical Application of Artificial Intelligence in Drug Discovery and Development
Valuation of Your Early Drug Candidate
Preparing Your Company for the M&A Process
A Medical Device Manufacturer's Guide to Selecting Suppliers
This white paper covers when to consider using suppliers, key differences between standard / OTS and custom part suppliers, tools and methods for managing suppliers, and when and how to transition between suppliers and internal resources.
Getting Ready for a Biopharma Partnering Deal
How to Apply the Golden Rule of Research to your Trial Master File
This whitepaper evaluates the regulations that support GDP, best practices on how document contributors can apply the golden rule of research to their TMF, how to avoid writing too many and unnecessary Note-to-Files (NTFs), and tips on becoming inspection ready and staying that way.
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Demystifying Tech M&A Valuation
Selling Your Healthcare or Life Sciences Company
This whitepaper gives medical groups, life sciences, and healthcare companies in the lower middle market an understanding of financing and M&A alternatives available, the role of financial buyers, key issues around selling equity in your business, and the typical financing and M&A process.
This whitepaper shares the most common scenarios that arise when you are selling your company, the choices you have when negotiating the terms of the sale, and which choices are your best ones, as supported by academic research are covered.
Pullan's Pieces - A Business Development View of the Oncology Landscape
In this whitepaper, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores the current oncology landscape and offers insightful perspective on trends, pipeline by indication, dealmaking, and the top ten oncology companies and the drugs they’re developing.